Search results
Results from the WOW.Com Content Network
Gemcitabine is a chemotherapy drug that works by killing any cells that are dividing. [10] Cancer cells divide rapidly and so are targeted at higher rates by gemcitabine, but many essential cells also divide rapidly, including cells in skin, the scalp, the stomach lining, and bone marrow, resulting in adverse effects.
In the United Kingdom, the National Institute for Health and Care Excellence (NICE), in a draft guidance issued in 2014, rejected the use of Abraxane in treatment due to concerns of side effects, efficacy, and cost relative to Gemzar (gemcitabine). [10] However, on 18 May 2017 NICE issued a reappraisal for the use of Abraxane in the UK.
IMM-101 is an immunomodulatory drug that is being studied to see if it is useful in chemotherapy. [1] It consists of heat-killed Mycobacterium obuense bacteria. It may have relatively few side effects compared to other drugs. [2] [3]
Threshold Pharmaceuticals' (NAS: THLD) TH-302 is a good drug. It just isn't a super-duper extraordinary drug. Apparently investors were looking for the latter and sent shares down 20% on Monday.
CagriSema’s side effects appeared to be similar to other drugs in the GLP-1 class; the company said the most common ones were gastrointestinal, with the “vast majority” mild to moderate and ...
Long-Term Side Effects of Parvo Even though your question was only about the vaccine, you need to be concerned about secondary infections and the other long-term side effects of a parvo infection (2).
Many studies show that antineoplastic drugs could have many side effects on the reproductive system, such as fetal loss, congenital malformation, and infertility. Health care workers who are exposed to antineoplastic drugs on many occasions have adverse reproductive outcomes such as spontaneous abortions, stillbirths, and congenital malformations.
Participants were required to have received at least one prior gemcitabine-containing regimen in the advanced disease setting. [ 2 ] The US Food and Drug Administration (FDA) granted the application for zanidatamab priority review , breakthrough therapy , and orphan drug designations.